| Stage | PSIX | % of rev | GLIBK | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $153M | 100.00% | $261M | 100.00% | GLIBK ×1.71 |
| Gross profit | $41M | 27.12% | $261M | 100.00% | GLIBK +72.9pp |
| Operating income | $24M | 15.68% | $29M | 11.11% | PSIX +4.6pp |
| Pre-tax income | $22M | 14.73% | $23M | 8.81% | PSIX +5.9pp |
| Net income | $17M | 11.05% | $16M | 6.13% | PSIX +4.9pp |
| Stage | PSIX | GLIBK | Gap · A − B |
|---|---|---|---|
| Revenue | $153M100.00% | $261M100.00% | GLIBK ×1.71 |
| Gross profit | 27.12%$41M | 100.00%$261M | GLIBK +72.9pp |
| Operating income | 15.68%$24M | 11.11%$29M | PSIX +4.6pp |
| Pre-tax income | 14.73%$22M | 8.81%$23M | PSIX +5.9pp |
| Net income |
| 11.05%$17M |
| 6.13%$16M |
| PSIX +4.9pp |
No disclosed counterparties: GLIBK.
None